Concentration-dependent modulation of four human brain sodium-channel α-subunits
Cell-based study · HEK293 cells stably expressing human Naᵥ1.1, Naᵥ1.2, Naᵥ1.3 or Naᵥ1.6 α-subunits without β-subunits [1]
Carbamazepine shifted steady-state inactivation toward hyperpolarized potentials. Differences among carbamazepine EC50 values were not significant. The α-subunit expression system limits extrapolation to neurons with β-subunits.
| Endpoint | Reported result | Reference |
|---|---|---|
| Half-maximal shift of steady-state inactivation midpoint for human Naᵥ1.1; not peak-current inhibition IC50. Table sample size in brackets. | EC50 134.6 ± 41.3 μM (mean ± SEM; n = 34) | [1] |
| Half-maximal shift of steady-state inactivation midpoint for human Naᵥ1.2; not peak-current inhibition IC50. Table sample size in brackets. | EC50 106.0 ± 30.7 μM (mean ± SEM; n = 37) | [1] |
| Half-maximal shift of steady-state inactivation midpoint for human Naᵥ1.3; not peak-current inhibition IC50. Table sample size in brackets. | EC50 49.2 ± 19.8 μM (mean ± SEM; n = 17) | [1] |
| Half-maximal shift of steady-state inactivation midpoint for human Naᵥ1.6; not peak-current inhibition IC50. Table sample size in brackets. | EC50 116.4 ± 28.5 μM (mean ± SEM; n = 18) | [1] |
| Fitted maximal absolute hyperpolarizing shift of inactivation midpoint | ΔVhmax Naᵥ1.1: 17.2 ± 2.6; Naᵥ1.2: 16.8 ± 2.3; Naᵥ1.3: 9.7 ± 1.5; Naᵥ1.6: 20.5 ± 2.3 mV (mean ± SEM; table n = 34, 37, 17, 18, respectively) | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- 10, 20, 50, 100 and 200 μM
- Exposure duration
- Each recording protocol lasted 2–2.5 min and was repeated at least twice per control/drug solution; no separate incubation duration specified.
- Method
- Extracellular application during whole-cell voltage clamp at 20–22°C. Steady-state inactivation used 2500 ms prepulses from −150 to −35 mV followed by a 25 ms step to −10 mV. Control solution before and after drug monitored rundown.
- Vehicle
- DMSO; Materials reports 0.05% for carbamazepine-containing solutions and no observed DMSO effect on Na+ currents.
- Reported limits
- No lot/purity reported in the selected Materials paragraph; no Adooq material tested.
Methods and source locations
Compound reported in the paper: Carbamazepine; Compound label in the paper: CBZ
Reported carbamazepine experiment; no salt conversion or validation of SKU A10179 lots.
Results: AED effects on the inactivation properties; Fig. 5B, Table 2; Fig. 1B protocol; Methods: Materials, whole-cell recordings, data analysis
Half-maximal shift of steady-state inactivation midpoint for human Naᵥ1.1; not peak-current inhibition IC50. Table sample size in brackets.: Whole-cell voltage clamp; Boltzmann inactivation fits followed by logistic concentration-response fit of absolute midpoint shift. — Table 2, Carbamazepine EC50 column, Naᵥ1.1 row; Methods: Data analysis
Half-maximal shift of steady-state inactivation midpoint for human Naᵥ1.2; not peak-current inhibition IC50. Table sample size in brackets.: Whole-cell voltage clamp; Boltzmann inactivation fits followed by logistic concentration-response fit of absolute midpoint shift. — Table 2, Carbamazepine EC50 column, Naᵥ1.2 row; Methods: Data analysis
Half-maximal shift of steady-state inactivation midpoint for human Naᵥ1.3; not peak-current inhibition IC50. Table sample size in brackets.: Whole-cell voltage clamp; Boltzmann inactivation fits followed by logistic concentration-response fit of absolute midpoint shift. — Table 2, Carbamazepine EC50 column, Naᵥ1.3 row; Methods: Data analysis
Half-maximal shift of steady-state inactivation midpoint for human Naᵥ1.6; not peak-current inhibition IC50. Table sample size in brackets.: Whole-cell voltage clamp; Boltzmann inactivation fits followed by logistic concentration-response fit of absolute midpoint shift. — Table 2, Carbamazepine EC50 column, Naᵥ1.6 row; Methods: Data analysis
Fitted maximal absolute hyperpolarizing shift of inactivation midpoint: Logistic fit; maximal fitted shift is distinct from observed shift at 200 μM. — Table 2, Carbamazepine ΔVhmax column; Fig. 5B; Results interpretation